Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine topical gel - BioDelivery Sciences International

Drug Profile

Clonidine topical gel - BioDelivery Sciences International

Alternative Names: ARC-4558

Latest Information Update: 31 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcion Therapeutics
  • Developer BioDelivery Sciences International
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Behavioural disorder therapies; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Feb 2017 BioDelivery Sciences returns back worldwide licensing rights for clonidine topical gel to Arcion Therapeutics
  • 13 Dec 2016 Discontinued - Phase-III for Diabetic neuropathies in USA due to lack of efficacy (Topical)
  • 01 Nov 2016 BioDelivery Sciences completes a phase IIb trial for Diabetic neuropathy in USA (NCT02643251)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top